The Technical Analyst
Akero Therapeutics Inc [AKRO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Akero Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.01% $21.00
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 447.90 mill |
| EPS: | -2.89 |
| P/E: | -7.27 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 68.95 mill |
| Avg Daily Volume: | 1.396 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.27 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.24x |
| Company: PE -7.27 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.96 (-81.14%) $-17.04 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 19.14 - 22.86 ( +/- 8.87%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Young Jonathan | Sell | 4 600 | Common Stock |
| 2024-04-01 | Young Jonathan | Sell | 400 | Common Stoek |
| 2024-03-13 | Yale Catriona | Sell | 723 | Common Stock |
| 2024-03-13 | White William Richard | Sell | 724 | Common Stock |
| 2024-03-13 | Cheng Andrew | Sell | 1 969 | Common Stock |
| INSIDER POWER |
|---|
| 52.13 |
| Last 100 transactions |
| Buy: 2 061 541 | Sell: 638 251 |
Forecast:
16:00 - $21.00
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $21.00
Forecast 2: 16:00 - $21.00
Forecast 3: 16:00 - $21.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $21.00 (1.01% ) |
| Volume | 0.537 mill |
| Avg. Vol. | 1.396 mill |
| % of Avg. Vol | 38.48 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AKRO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $18.53 | N/A | Active |
|---|
AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-04-20 12:15:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Akero Therapeutics, Inc. - Akro
New york , april 20, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of akero therapeutics, inc. ("akero" or the "company") (nasdaq: akro). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2024-04-04 19:25:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Akero Therapeutics, Inc. - Akro
New york , april 4, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of akero therapeutics, inc. ("akero" or the "company") (nasdaq: akro). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2024-04-02 18:05:00 - Press Release
Ademi Llp Investigates Claims Of Securities Fraud Against Akero Therapeutics, Inc.
Milwaukee , april 2, 2024 /prnewswire/ -- ademi llp is investigating possible securities fraud claims against akero (nasdaq: akro). the investigation results from inaccurate statements akero may have made regarding its business operations and prospects.
2024-04-01 07:30:00 - Press Release
Levi & Korsinsky Reminds Shareholders Of An Investigation Into Akero Therapeutics, Inc. (akro) Regarding Potential Securities Fraud Allegations
New york, ny / accesswire / april 1, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of akero therapeutics, inc. ("akero therapeutics") (nasdaq:akro) concerning possible violations of federal securities laws. on october 10, 2023, akro announced efruxifermin (efx) failed to meet the primary endpoint of fibrosis improvement at 36 weeks in the phase 2b symmetry trial in nash patients with compensated cirrhosis.
2024-03-28 16:50:00 - Press Release
Akero Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky To Discuss Your Rights – Akro
New york, ny / accesswire / march 28, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of akero therapeutics, inc. ("akero therapeutics") (nasdaq:akro) concerning possible violations of federal securities laws. on october 10, 2023, akro announced efruxifermin (efx) failed to meet the primary endpoint of fibrosis improvement at 36 weeks in the phase 2b symmetry trial in nash patients with compensated cirrhosis.
Latest News
2024-03-05 15:16:06 - Zacks Investment Research
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
2024-03-04 14:49:04 - Seeking Alpha
Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program
Akero Therapeutics, Inc. preliminary positive 96-week results from the phase 2b HARMONY study achieved, which used EFX for the treatment of pre-cirrhotic MASH patients with F2-F3 Fibrosis. The global non-alcoholic steatohepatitis market size is expected to reach $14.53 billion by 2028. 96-week results from the phase 2b SYMMETRY study, using EFX for the treatment of patients with compensated cirrhosis (F4) MASH, expected in Q1 of 2024.
2024-03-04 06:11:13 - Reuters
Akero's lead drug helps improve scarring in fatty liver disease patients
Akero Therapeutics said on Monday its lead experimental drug to treat a type of fatty liver disease helped improve scarring in patients' organ after 96 weeks, meeting the main goal of a mid-stage study.
2024-03-01 10:56:10 - Zacks Investment Research
Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know
The mean of analysts' price targets for Akero Therapeutics, Inc. (AKRO) points to a 58.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-02-29 08:00:00 - GlobeNewsWire
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data
2024-02-05 10:56:08 - Zacks Investment Research
Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now
Akero Therapeutics, Inc. (AKRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2024-01-30 10:41:20 - Zacks Investment Research
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Perspective Therapeutics (CATX) have performed compared to their sector so far this year.
2024-01-09 15:55:44 - Schaeffers Research
Biotech Stock Rally Could Soon Take a Breather
The shares of Akero Therapeutics Inc (NASDAQ:AKRO) have been steadily climbing from their November lows following a steep early October bear gap , though pressure seems to have appeared at the $25 level.
2024-01-03 08:15:00 - GlobeNewsWire
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 09:45 a.m. P.T. in San Francisco, CA.
2023-11-10 08:57:00 - GlobeNewsWire
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting® 2023
Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due to NASH/MASH